
Mary Hormese
26 posts


@SIDPharm @ASHP_EMPharm @CIDJournal @VBZafonte @Annabiotics @moore_wjustin @jwagsIDPharmD @OncIDPharmd @IDstewardship Use cefazolin even if anaphylaxis to PCN.
English

New in @CIDJournal:
"approximately 40% of patients undergoing a major elective surgery did not receive guideline-adherent antimicrobial prophylaxis, largely due to unnecessary use of vancomycin..."
Any ideas to⬆️guideline adherence? #IDTwitter #TwitteRx
academic.oup.com/cid/advance-ar…


English

This isn’t news to many but glad that it’s in the guidelines for those who still believe in cross-reactivity between PCN and ceftriaxone (and many other good cephs)
aaaai.org/Aaaai/media/Me…

English

Truly and honor to be recognized by the @accpemedprn. Credit goes to my monumental mentors @MaryHormese, @MadhatterpharmD, and the forever twitter-less Neal Lyons.
UIC Dept Pharmacy Practice@UICPhPr
Dr. Marc McDowell @PharmD_ED is the recipient of the American College of Clinical Pharmacy Emergency Medicine PRN @accpemedprn New Clinical Practitioner Award.
English

Pharmacy PGY-2 in EM officially accredited. Kudos to our RPD, @RMok12, and the rest of the group for the hard work.

English
Mary Hormese retweetledi

👏👏 extremely clever study confirming (yet again) that contrast nephropathy is a myth.
Robert Goulden@EMrobg
Our new paper in @JAMAInternalMed: is IV contrast nephrotoxic? Lots of studies say no, but have ⬆️risk of confounding: people who get contrast ≠ people who don't get it. We used a natural experiment to try to overcome this bias jamanetwork.com/journals/jamai… 1/5
English
Mary Hormese retweetledi

@ASHP_EMPharm @garyDpeksa pubmed.ncbi.nlm.nih.gov/33725284/
I think Dr. Hormese's work showed similar results back in March.
English

@EMPoisonPharmD @___nonsequitur @EDPharmHand @ASHP_EMPharm @accpemedprn @ACCP Very true. Nonetheless, our ~2yr experience since we switched to low-dose is very encouraging and hope will help others who still use a higher dose PCC or Andexxa.
English

@MaryHormese @___nonsequitur @EDPharmHand @ASHP_EMPharm @accpemedprn @ACCP descriptive data is good, but not powered would mean also not powered to see an effect in either direction correct? If null means outcomes are same w/ each dose then Rejecting null->outcomes could be better OR worse, larger sample could change observation. Still good to report🤷♂️
English

Super excited about our study comparing high- and low dose 4F-PCC for DOAC reversal! Special shout out to @___nonsequitur @EDPharmHand
rdcu.be/cgTzd
@ASHP_EMPharm @accpemedprn @ACCP
English

@EMPoisonPharmD @___nonsequitur @EDPharmHand @ASHP_EMPharm @accpemedprn @ACCP We didn't have power to show superiority 2/2 small sample, hence kept it as a descriptive analysis. Would have loved to though if we had more patients.
English

@MaryHormese @___nonsequitur @EDPharmHand @ASHP_EMPharm @accpemedprn @ACCP Nice work, haven’t dived into it, was it powered to see difference in outcome w/ low sample size? Either way good effort on trying to measure if dosing strategy impacts things. Hard enough to measure outcomes alone in doac bleeding
English
Mary Hormese retweetledi

Our team is hiring an EM pharmacist for nights (7 on/off)! Louisville’s only level 1 trauma center with a robust clinical pharmacy practice model in our ED. Please share to whoever you think may be interested. DM for details social.icims.com/viewjob/pt1610…
English
Mary Hormese retweetledi

@garyDpeksa So far no. Esp with the time involved and room constraints in ED. Things might change tho...
English
Mary Hormese retweetledi








